Established in tandem with Singapore's national Biomedical Sciences Initiatives, the Bioethics Advisory Committee (BAC) was established by the Singapore Cabinet in December 2000 to examine the potential ethical, legal, and social issues arising from Singapore's biomedical research sector, and to recommend policy to Singapore's government. BAC's deliberations on embryonic stem cell research helped shape the government policies that helped Singapore pursue its goal of becoming one of the biggest investors of embryonic stem cell research in the early twenty-first century.